+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07554521

Evaluating Tislelizumab Plus Chemotherapy in US Minority Patients with Advanced Unresectable or Metastatic Gastric, Gastroesophageal Adenocarcinoma, or Esophageal Squamous Cell Carcinoma

Led by BeOne Medicines · Updated on 2026-10-16

30

Participants Needed

9

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the clinical effects of tislelizumab combined with chemotherapy in US racial and ethnic minority patients who have HER2-negative, PD-L1-positive, locally advanced unresectable or metastatic gastric or gastroesophageal adenocarcinoma GACGEA or esophageal squamous cell carcinoma ESCC. This Phase 2 study aims to assess the pharmacokinetics, activity, and safety of this combination treatment over a period of up to approximately 6 years. Participants will receive tislelizumab given by intravenous infusion at either 200 mg every 3 weeks or 150 mg every 2 weeks, depending on the chemotherapy regimen. The chemotherapy options include FOLFOX oxaliplatin, leucovorin, and 5-fluorouracil, CAPOX oxaliplatin plus oral capecitabine, or cisplatin plus 5-fluorouracil, administered in cycles every 2 or 3 weeks. The study is open-label and non-randomized with two study arms based on the type of cancer. During the study, participants will be monitored for adverse events and serious adverse events for about 12 months. Researchers will also assess tumor response, measure serum levels of tislelizumab, and check for antidrug antibodies. Eligibility assessments include tumor PD-L1 status and organ function tests. The study includes regular visits for treatment administration and safety evaluations, with participants followed for up to six years to gather long-term data.

CONDITIONS

Brief Title

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Research Team

S

Study Director

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here